Literature DB >> 18586992

Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder.

Martha Sajatovic1, Kousick Biswas, Amy K Kilbourne, Howard Fenn, William Williford, Mark S Bauer.   

Abstract

OBJECTIVE: Clinical characteristics, adverse effects of medication, and treatment attitudes have been associated with adherence in bipolar populations in cross-sectional studies. The aim of this secondary analysis from a larger study was to identify the association between baseline variables and average treatment adherence over a subsequent three-year period.
METHODS: Veterans with bipolar disorder were evaluated on self-reported adherence status at baseline and every six months over a three-year period. The sample was dichotomized into two clinically relevant categories: those who were primarily adherent and those who were primarily nonadherent. Demographic and clinical variables were examined for the two groups of patients in relation to their average adherence over the three-year period.
RESULTS: The study recruited a sample of 306 persons with severe bipolar disorder. The sample was predominantly male (278 men, or 91%), with a mean+/-SD age of 46.6+/-10.1 years. A total of 240 individuals (78%) were largely adherent to treatment, and 37 individuals (12%) were largely nonadherent to treatment. Nonadherent individuals were less likely to be on intensive somatotherapy regimens (p=.001); experienced more barriers to care, including lack of telephone access (p<.05) and life obligations and commitments (p<.05); and had more prior suicide attempts (p=.003).
CONCLUSIONS: Nonadherent individuals with bipolar disorder received less intensive pharmacologic treatments, had more suicide attempts, and experienced more barriers to care than adherent individuals. Nonadherence may have system as well as patient components. Consideration of nonadherence as a function of both patient factors and system factors will enhance our ability to understand nonadherence and intervene more effectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586992     DOI: 10.1176/ps.2008.59.7.753

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  21 in total

1.  Methods to limit attrition in longitudinal comparative effectiveness trials: lessons from the Lithium Treatment - Moderate dose Use Study (LiTMUS) for bipolar disorder.

Authors:  Louisa G Sylvia; Noreen A Reilly-Harrington; Andrew C Leon; Christine I Kansky; Terence A Ketter; Joseph R Calabrese; Michael E Thase; Charles L Bowden; Edward S Friedman; Michael J Ostacher; Dan V Iosifescu; Joanne Severe; Michelle Keyes; Andrew A Nierenberg
Journal:  Clin Trials       Date:  2011-11-10       Impact factor: 2.486

2.  Predictors of non-stabilization during the combination therapy of lithium and divalproex in rapid cycling bipolar disorder: a post-hoc analysis of two studies.

Authors:  Keming Gao; David E Kemp; Zuowei Wang; Stephen J Ganocy; Carla Conroy; Marry Beth Serrano; Martha Sajatovic; Robert L Findling; Joseph R Calabrese
Journal:  Psychopharmacol Bull       Date:  2010

Review 3.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

4.  Psychotherapy for Bipolar Disorder in Adults: A Review of the Evidence.

Authors:  Holly A Swartz; Joshua Swanson
Journal:  Focus (Am Psychiatr Publ)       Date:  2014

5.  Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication.

Authors:  Martha Sajatovic; Jennifer Levin; Edna Fuentes-Casiano; Kristin A Cassidy; Curtis Tatsuoka; Janis H Jenkins
Journal:  Compr Psychiatry       Date:  2010-09-01       Impact factor: 3.735

6.  Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Natalie Bareis; Juan Lu; Cynthia K Kirkwood; Susan G Kornstein; Elwin Wu; Briana Mezuk
Journal:  J Affect Disord       Date:  2018-05-29       Impact factor: 4.839

7.  Medication adherence in a comparative effectiveness trial for bipolar disorder.

Authors:  L G Sylvia; N A Reilly-Harrington; A C Leon; C I Kansky; J R Calabrese; C L Bowden; T A Ketter; E S Friedman; D V Iosifescu; M E Thase; M J Ostacher; M Keyes; D Rabideau; A A Nierenberg
Journal:  Acta Psychiatr Scand       Date:  2013-10-03       Impact factor: 6.392

8.  Associations of Comorbid Anxiety With Medication Adherence and Psychiatric Symptomatology in a Population of Nonadherent Bipolar Disorder Subjects.

Authors:  Awais Aftab; Jennifer Levin; Michelle Aebi; Chetan Bhat; Martha Sajatovic
Journal:  J Nerv Ment Dis       Date:  2018-04       Impact factor: 2.254

9.  Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection.

Authors:  Wissam El-Hage; Simon A Surguladze
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Adjunctive Behavioral Activation for the Treatment of Bipolar Depression: A Proof of Concept Trial.

Authors:  Lauren M Weinstock; Caitlin Melvin; Mary K Munroe; Ivan W Miller
Journal:  J Psychiatr Pract       Date:  2016-03       Impact factor: 1.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.